Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albrektsen, T.
Right arrow Articles by Fleckner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albrektsen, T.
Right arrow Articles by Fleckner, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 51:1042-1051, 2002
© 2002 by the American Diabetes Association, Inc.

Novel Genes Regulated by the Insulin Sensitizer Rosiglitazone During Adipocyte Differentiation

Tatjana Albrektsen1,2, Klaus Stensgaard Frederiksen1, William E. Holmes1, Esper Boel1, Karen Taylor3, and Jan Fleckner1

1 Department of Molecular Genetics, Novo Nordisk, Bagsvaerd, Denmark
2 Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
3 Research & Development, Amersham Pharmacia Biotech, Bucks, U.K.

Thiazolidinediones (TZDs) are a new class of compounds that improve insulin sensitivity in type 2 diabetic patients as well as in rodent models of this disease. These compounds act as ligands for a member of the nuclear hormone receptor superfamily, peroxisome proliferator–activated receptor-{gamma} (PPAR-{gamma}), which is highly expressed in adipose tissue and, moreover, has been shown to play an important role in adipocyte differentiation. The strong correlation between the antidiabetic activity of TZDs and their ability to activate PPAR-{gamma} suggests that PPAR-{gamma}, through downstream-regulated genes, mediates the effects of TZDs. In this report, we present the isolation and characterization of 81 genes, encoding proteins of known function, differentially expressed during TZD-stimulated differentiation of 3T3-L1 cells. By the use of different reverse– Northern blot techniques, the differential expression of 50 of these genes could be verified, and 21 genes were specifically regulated by a potent TZD during the course of adipocyte differentiation, whereas no effect of a PPAR-{gamma} antagonist could be observed in mature adipocytes. The differential expression of a large fraction of the isolated genes was also shown to occur in white adipose tissue of ob/ob mice treated with rosiglitazone; combined, our results suggest that an important effect of rosiglitazone in adipose tissue is based on activation of PPAR-{gamma} in preexisting preadipocytes found among the mature adipocytes, resulting in subsequent adipocyte differentiation.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kolak, H. Yki-Jarvinen, K. Kannisto, M. Tiikkainen, A. Hamsten, P. Eriksson, and R. M. Fisher
Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 720 - 724.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Allen, F. Zhang, S. A. Moodie, L. E. Clemens, A. Smith, F. Gregoire, A. Bell, G. E.O. Muscat, and T. A. Gustafson
Halofenate Is a Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulator With Antidiabetic Activity
Diabetes, September 1, 2006; 55(9): 2523 - 2533.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. Nielsen, L. Grontved, H. G. Stunnenberg, and S. Mandrup
Peroxisome Proliferator-Activated Receptor Subtype- and Cell-Type-Specific Activation of Genomic Target Genes upon Adenoviral Transgene Delivery
Mol. Cell. Biol., August 1, 2006; 26(15): 5698 - 5714.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
C. R. Benton, D. P. Y. Koonen, J. Calles-Escandon, N. N. Tandon, J. F. C. Glatz, J. J. F. P. Luiken, J. J. Heikkila, and A. Bonen
Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle
J. Physiol., May 15, 2006; 573(1): 199 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Y. Yin, H. Yuan, C. Wang, N. Pattabiraman, M. Rao, R. G. Pestell, and R. I. Glazer
3-Phosphoinositide-Dependent Protein Kinase-1 Activates the Peroxisome Proliferator-Activated Receptor-{gamma} and Promotes Adipocyte Differentiation
Mol. Endocrinol., February 1, 2006; 20(2): 268 - 278.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Grohmann, M. Sabin, J. Holly, J. Shield, E. Crowne, and C. Stewart
Characterization of differentiated subcutaneous and visceral adipose tissue from children: the influences of TNF-{alpha} and IGF-I
J. Lipid Res., January 1, 2005; 46(1): 93 - 103.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. R. Kast-Woelbern, S. L. Dana, R. M. Cesario, L. Sun, L. Y. de Grandpre, M. E. Brooks, D. L. Osburn, A. Reifel-Miller, K. Klausing, and M. D. Leibowitz
Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor {gamma} and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis
J. Biol. Chem., June 4, 2004; 279(23): 23908 - 23915.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Tonelli, W. Li, P. Kishore, U. B. Pajvani, E. Kwon, C. Weaver, P. E. Scherer, and M. Hawkins
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Diabetes, June 1, 2004; 53(6): 1621 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. C. Benson, H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz
Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity
Hypertension, May 1, 2004; 43(5): 993 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
K. S. Frederiksen, E. M. Wulff, P. Sauerberg, J. P. Mogensen, L. Jeppesen, and J. Fleckner
Prediction of PPAR-{alpha} ligand-mediated physiological changes using gene expression profiles
J. Lipid Res., March 1, 2004; 45(3): 592 - 601.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. S. Lihn, B. Richelsen, S. B. Pedersen, S. B. Haugaard, G. S. Rathje, S. Madsbad, and O. Andersen
Increased expression of TNF-{alpha}, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels
Am J Physiol Endocrinol Metab, November 1, 2003; 285(5): E1072 - E1080.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. K. Kim, J. J. Fillmore, O. Gavrilova, L. Chao, T. Higashimori, H. Choi, H.-J. Kim, C. Yu, Y. Chen, X. Qu, et al.
Differential Effects of Rosiglitazone on Skeletal Muscle and Liver Insulin Resistance in A-ZIP/F-1 Fatless Mice
Diabetes, June 1, 2003; 52(6): 1311 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies
PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion
Diabetes, February 1, 2003; 52(2): 291 - 299.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.